Does the Immune System Naturally Protect Against Cancer?

The importance of the immune system in conferring protection against pathogens like viruses, bacteria, and parasitic worms is well established. In contrast, there is a long-lasting debate on whether cancer prevention is a primary function of the immune system. The concept of immunological surveillance of cancer was developed by Lewis Thomas and Frank Macfarlane Burnet more than 50 years ago. We are still lacking convincing data illustrating immunological eradication of precancerous lesions in vivo. Here, I present eight types of evidence in support of the cancer immunosurveillance hypothesis. First, primary immunodeficiency in mice and humans is associated with increased cancer risk. Second, organ transplant recipients, who are treated with immunosuppressive drugs, are more prone to cancer development. Third, acquired immunodeficiency due to infection by human immunodeficiency virus (HIV-1) leads to elevated risk of cancer. Fourth, the quantity and quality of the immune cell infiltrate found in human primary tumors represent an independent prognostic factor for patient survival. Fifth, cancer cells harbor mutations in protein-coding genes that are specifically recognized by the adaptive immune system. Sixth, cancer cells selectively accumulate mutations to evade immune destruction (“immunoediting”). Seventh, lymphocytes bearing the NKG2D receptor are able to recognize and eliminate stressed premalignant cells. Eighth, a promising strategy to treat cancer consists in potentiating the naturally occurring immune response of the patient, through blockade of the immune checkpoint molecules CTLA-4, PD-1, or PD-L1. Thus, there are compelling pieces of evidence that a primary function of the immune system is to confer protection against cancer.

[1]  T. Oshikiri,et al.  CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. , 2003, Cancer research.

[2]  A. Hayday,et al.  Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.

[3]  M BURNET,et al.  Cancer—A Biological Approach* , 1957, British medical journal.

[4]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[5]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[6]  R. Hoover,et al.  Risk of cancer in renal-transplant recipients. , 1973, Lancet.

[7]  L. Lanier,et al.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Notarangelo,et al.  Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. , 1997, Journal of immunology.

[9]  Ariadni Mavrou,et al.  Development of cancer in patients with primary immunodeficiencies. , 2008, Anticancer research.

[10]  C. Creaser,et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.

[11]  M. Burnet Cancer—A Biological Approach , 1957, British medical journal.

[12]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[13]  J. Peto,et al.  PROSPECTIVE STUDY OF CANCER IN PATIENTS WITH HYPOGAMMAGLOBULINAEMIA , 1985, The Lancet.

[14]  S. Rosenberg,et al.  Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[15]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[16]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[17]  W. Savage,et al.  GYNAECOLOGISTS' ATTITUDES TO ABORTION , 1989, The Lancet.

[18]  F. Nagengast,et al.  Colorectal cancer in patients with X-linked agammaglobulinaemia , 1993, The Lancet.

[19]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[20]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[21]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Rosenberg,et al.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.

[23]  T. Spies,et al.  Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB , 1999 .

[24]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[25]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[26]  F. Davi,et al.  Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[28]  A. Tutt,et al.  Immunological Visibility: Posttranscriptional Regulation of Human NKG2D Ligands by the EGF Receptor Pathway , 2014, Science Translational Medicine.

[29]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[30]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[31]  Olivia Keiser,et al.  Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.

[32]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[33]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[34]  G. Opelz,et al.  Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[36]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[37]  M. Guiguet,et al.  Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.

[38]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  David Haussler,et al.  Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.

[40]  B. Lippitz,et al.  Cytokine patterns in patients with cancer: a systematic review. , 2013, The Lancet. Oncology.

[41]  S. Ferrone,et al.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.

[42]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[43]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[44]  F. Burnet The concept of immunological surveillance. , 1970, Progress in experimental tumor research.

[45]  N. Hayashi,et al.  Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid , 2003, International journal of cancer.

[46]  E. Schaftingen,et al.  High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. , 2001, Cancer research.

[47]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[48]  J. Blay,et al.  Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. , 2013, Cancer research.

[49]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[50]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[51]  T. Schulz Cancer and viral infections in immunocompromised individuals , 2009, International journal of cancer.

[52]  S. Bauer,et al.  Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Hayday,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[54]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[55]  D. Dunn,et al.  CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS , 1978, The Lancet.

[56]  R. Vaughan,et al.  An NKG2D-Mediated Human Lymphoid Stress Surveillance Response with High Interindividual Variation , 2011, Science Translational Medicine.

[57]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[58]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[59]  A. Gemma,et al.  Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.

[60]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[61]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[62]  M. Smyth,et al.  NKG2D function protects the host from tumor initiation , 2005, The Journal of experimental medicine.

[63]  Boris Pasche,et al.  TGF-β: duality of function between tumor prevention and carcinogenesis. , 2014, Journal of the National Cancer Institute.

[64]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[65]  J. Shabanowitz,et al.  The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. , 1998, Cancer research.

[66]  B. Mueller,et al.  Cancer in children with primary or secondary immunodeficiencies. , 1995, The Journal of pediatrics.

[67]  Yuchen Jiao,et al.  Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer , 2014, Science.

[68]  Richard L. Abbott,et al.  A Follow-up Study , 1990 .

[69]  L. Feuk,et al.  Genome-wide association study of susceptibility loci for cervical cancer. , 2013, Journal of the National Cancer Institute.

[70]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  T. Karlsen,et al.  Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms , 2007, Hepatology.

[72]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[73]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[74]  J. Cayuela,et al.  BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia1 , 2006, The Journal of Immunology.

[75]  R. Gatti,et al.  Occurrence of malignancy in immunodeficiency diseases: A literature review , 1971, Cancer.

[76]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[77]  F. Garrido,et al.  Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors , 1999, International journal of cancer.

[78]  Yao-Tseng Chen,et al.  Characterization of human colon cancer antigens recognized by autologous antibodies , 1998, International journal of cancer.

[79]  T. Oshikiri,et al.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.

[80]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[81]  L. Thomas On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.

[82]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[83]  Orchard Tj Letter: Mobile coronary care. , 1974 .

[84]  M. R. Oliva,et al.  A new beta 2 microglobulin mutation found in a melanoma tumor cell line. , 1999, Tissue antigens.

[85]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[86]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[87]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[88]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[89]  S. Cole,et al.  A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals , 2009, Journal of acquired immune deficiency syndromes.

[90]  Jae Hyun Kim,et al.  High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer , 2008, British Journal of Cancer.

[91]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[92]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[93]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[94]  F. Greco,et al.  Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  M. Smyth,et al.  Immune surveillance of tumors. , 2007, The Journal of clinical investigation.

[96]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[97]  R. Palmqvist,et al.  High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer , 2007, Clinical Cancer Research.

[98]  P. Coulie,et al.  A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. , 2001, Cancer research.

[99]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[100]  G. Opelz,et al.  Cytomegalovirus Prophylaxis and Graft Outcome in Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[101]  K. O'Byrne,et al.  Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  N. Levine THE BIOLOGICAL APPROACH , 1950 .

[103]  S. Gasser,et al.  Ras Activation Induces Expression of Raet1 Family NK Receptor Ligands , 2012, The Journal of Immunology.

[104]  B. O'Sullivan,et al.  The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. , 1996, Transplantation.

[105]  S. Crystal,et al.  HIV as an independent risk factor for incident lung cancer , 2012, AIDS.

[106]  S. Bahram,et al.  Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[107]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[108]  G. Edgren,et al.  Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008—A Swedish population‐based study , 2013, International journal of cancer.

[109]  T. Wheeler,et al.  Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. , 2000, Cancer research.

[110]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[111]  J. Nesland,et al.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[112]  D. Raulet,et al.  RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry , 2012, The Journal of experimental medicine.

[113]  D. Nicol,et al.  Non-melanoma skin cancer risk in the Queensland renal transplant population. , 2002 .